Recent developments
Precision medicine shifts
Japan authorized the first tumor‑agnostic ALK inhibitor with Chugai’s Alecensa for ALK‑positive solid tumors, supported by the TACKLE study and expansion of FoundationOne CDx as its companion diagnostic. The FDA cleared ctDNA‑guided adjuvant use of Tecentriq in MIBC with Signatera CDx, while Roche to acquire PathAI integrates AI‑enabled digital pathology into diagnostics and trial workflows.
Immunology and renal updates
The FDA expanded VYVGART/VYVGART Hytrulo to all adult gMG serotypes; in nephrology, Chugai and Nippon Shinyaku filed Gazyva for idiopathic nephrotic syndrome. In gastroenterology, TREMFYA in perianal fistulizing Crohn’s disease showed efficacy, and Omvoh reported durable four‑year disease clearance in ulcerative colitis.
Obesity therapies and capacity
New data highlighted GLP‑1 demand: oral semaglutide in OASIS 4 delivered 21.6% weight loss in early responders, and STEP UP’s 7.2 mg arm achieved 21.0% mean loss with ~28% in early responders. Maintenance studies showed weight preservation after switching to oral Foundayo (orforglipron); to meet volumes, Eli Lilly committed $4.5B to expand Indiana manufacturing.
Manufacturing and isotopes
Amgen allocated $300M to expand U.S. biologics capacity at Juncos, while a consortium began building a facility in Mol to produce actinium‑225 for radiopharmaceuticals. Asahi Kasei will realign material supply by FY2030, exiting low‑margin derivatives and following its AMEC ethylene shutdown.
Regional regulatory moves
Japan broadened adult RSV vaccination with GSK’s Arexvy to at‑risk 18–49‑year‑olds. In China, GSK partnered with CTTQ for the exclusive launch of bepirovirsen pending Priority Review. In Japan, Asahi Kasei Therapeutics started a Phase III to evaluate extended teriparatide use for high‑risk osteoporosis.